[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567501":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":29,"centralContacts":34,"locations":40,"responsibleParty":59,"collaborators":28,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":28,"maxAge":70,"enrollmentInfo":71,"targetDuration":28,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":28,"overallStatus":43,"whyStopped":28,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"N.N. Petrov National Medical Research Center of Oncology","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Generalized \u002F metastatic GD2-positive rhabdomyosarcoma","EXPERIMENTAL","Generalized \u002F metastatic GD2-positive rhabdomyosarcoma after progression on 1st line of chemotherapy.\n\nChemotherapy options:\n\n• CARBO(CARBOPLATIN) + ETO(ETOPOSIDE), IFO(IFOSFAMIDE) + ETO(ETOPOSIDE), CARBO(CARBOPLATIN) + IFO(IFOSFAMIDE) (rhabdomyosarcoma)\n\n\\+ 6 consecutive cycles of dinutuximab beta immunotherapy",[13],"Drug: dinutuximab beta",{"label":15,"type":10,"description":16,"interventionNames":17},"Generalized \u002F metastatic GD2-positive Ewing sarcoma","Generalized \u002F metastatic GD2-positive Ewing sarcoma after progression on 1st line of chemotherapy.\n\n• ICE (IFOSFAMIDE+CARBOPLATIN+ETOPOSIDE), TEM(TEMOZOLOMIDE+IRINOTECAN), VCT(VINCRISTINE+CYCLOPHOSPHAN+TOPOTECAN), TC(CYCLOPHOSPHAN+TOPOTECAN), TT(TEMOZOLOMIDE+TOPOTECAN), GEM\u002FTAX(GEMCITABINE+DOCETAXEL) (Ewing's sarcoma)\n\n\\+ 6 consecutive cycles of dinutuximab beta immunotherapy",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Generalized \u002F metastatic GD2-positive osteosarcoma","Generalized \u002F metastatic GD2-positive osteosarcoma after progression on 1st line of chemotherapy.\n\n• ICE(IFOSFAMIDE+CARBOPLATIN+ETOPOSIDE), IE (IFOSFAMIDE+ETOPOSIDE), CARBOPLATIN+ ETOPOSIDE, Аi(DOXORUBICIN+IFOSFAMIDE), IFO(IFOSFAMIDE), GEM\u002FTAX(GEMCITABINE+DOCETAXEL) (osteosarcoma)\n\n\\+ 6 consecutive cycles of dinutuximab beta immunotherapy",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","dinutuximab beta","Chemotherapy + Immunotherapy (dinutuximab beta)",[15,19,9],null,[30],{"name":31,"affiliation":32,"role":33},"Svetlana Kulyova, MD, Phd","Head of Children's Oncology Department","PRINCIPAL_INVESTIGATOR",[35],{"name":31,"role":36,"phone":37,"phoneExt":38,"email":39},"CONTACT","+78124399555","+79213357588","Kulevadoc@yandex.ru",[41],{"facility":42,"status":43,"city":44,"state":28,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Kulyova Svetlana","RECRUITING","Saint Petersburg","194362","Russia","RU",{"type":49,"coordinates":50},"Point",[51,52],30.31413,59.93863,{"lat":52,"lon":51},[55,58],{"name":56,"role":36,"phone":57,"phoneExt":28,"email":39},"Svetlana Kulyova, MD, PhD","+781243995553301",{"name":56,"role":36,"phone":38,"phoneExt":28,"email":39},{"type":60,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100567501","phase-3-chemo-immunotherapy-in-patients-under-18-years-of-age-with-bone-and-soft-tissue-sarcomas-100567501",false,"NCT06669013","Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas","A Randomized, Multicenter, Open-label Phase III Study of Dinutuximab Beta With Investigator's Choice of Chemotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas With High Levels of GD2 Expression and Disease Progression During 1st Line Chemotherapy","FollowTheDIN","Inclusion Criteria:\n\n1. Signed written informed consent form;\n2. Age under 18 years of age;\n3. Histologically confirmed GD2-positive osteogenic sarcoma, Ewing's sarcoma, soft tissue and undifferentiated sarcomas;\n4. Prior to study enrollment, patients must have been treated with one or more lines of adequate chemotherapy and must have relapsed on this therapy or have refractoriness to it;\n5. General satisfactory condition of the patient (Lansky scale activity 80-100% (children under 16 years of age), Karnofsky scale 80-100% (children over 16 years of age); ECOG - 0-1);\n6. Sufficient cardiopulmonary reserves of the patient's organism (ECG (ELECTROCARDIOGRAPHY) data within normal limits, ventricular ejection fraction \\> 75% of the upper limit of normal;\n7. Adequate liver function (ALT (ALANINE AMINOTRANSFERASE) ≤ 2.5 \\* VGN, AST (ASPARTATE AMINOTRANSFERASE) ≤ 2.5 \\* VGN), kidney (creatinine \\\u003C1.5 \\* VGN), red bone marrow (granulocytes\\> 2.0 \\* 109\u002FL, platelets\\> 150 \\* 109\u002FL).\n\n   Six months later, two additional criteria were formulated:\n8. Life expectancy at the time of initiation of therapy within the framework of the study is not less than 12 months\n9. Oligometastasis disease (presence of 1 to 5 distant metastatic foci) at restaging at the time of the decision to include the patient in the study;\n\nExclusion Criteria:\n\n1. Withdrawal of consent by the patient or his\u002Fher parent\u002Fguardian.\n2. Exclusion of the patient by the investigator for safety or ethical reasons.","ALL","18 Years",{"count":72,"type":73},40,"ESTIMATED","INTERVENTIONAL",[76],"PHASE3","Data from 40 patients are planned to be included in the study to randomize approximately 10 patients.\n\nThis study involves patients with advanced\u002Fmetastatic GD2-positive rhabdomyosarcoma after progression on 1st line of chemotherapy, advanced\u002Fmetastatic GD2-positive Ewing sarcoma after progression on 1st line of chemotherapy and advanced\u002Fmetastatic GD2-positive osteosarcoma after progression on 1st line of chemotherapy.\n\nAll patients will receive therapy until disease progression (a total of 6 courses of immunotherapy).\n\nThe primary objective of the study is to determine the efficacy and safety of dinutuximab beta with investigator's choice of chemotherapy.",[79,80,81],"Bone Sarcoma","Embryonal Rhabdomyosarcoma","Alveolar Rhabdomyosarcoma","2024-10-31",{"date":84,"type":85},"2024-11-01","ACTUAL",{"date":87,"type":85},"2021-05-20",{"date":89,"type":73},"2025-09",{"name":5,"class":6},1]